SAFETY ANALYSIS OF THE IMMUNOSUPPRESSANTS USE IN RENAL FAILURE PATIENTS

Authors

  • Fernanda Toaldo Pontifícia Universidade Católica do Paraná - PUCPR Rua Imac. Conceição, 1155 - Prado Velho, Curitiba - PR, 80215-901
  • Flavia Lorenzen dos Santos Pontifícia Universidade Católica do Paraná - PUCPR Rua Imac. Conceição, 1155 - Prado Velho, Curitiba - PR, 80215-901
  • Fernanda Cristina Ostrovski Sales Pontifícia Universidade Católica do Paraná - PUCPR Rua Imac. Conceição, 1155 - Prado Velho, Curitiba - PR, 80215-901
  • Jaqueline de Jesus Aschenbrenner Pontifícia Universidade Católica do Paraná - PUCPR Rua Imac. Conceição, 1155 - Prado Velho, Curitiba - PR, 80215-901

DOI:

https://doi.org/10.14450/2318-9312.v32.e4.a2020.pp374-382

Keywords:

clinical pharmacy, immunosuppressants, adverse drug reactions

Abstract

Acute renal failure (ARF) and chronic renal failure (CRF) are pathologies with increasing incidence recently in Brazil. According to the Brazilian Society of Nephrology (2018), the number of patients with these comorbidities has increased by approximately 200% in 16 years, with organ transplantation as an alternative treatment. One of the main post-renal transplant therapies is the use of immunosuppressants to contain graft rejection. However, the safety of this pharmacotherapy is still discussed, due to the high probability of adverse reactions occurring. This study presented and analyzed numerical data regarding the occurrence of adverse drug reaction (ADR) related to immunosuppressants used as pharmacotherapy by patients with ARF or CRF hospitalized in a University Hospital of Curitiba county, PR. It is a retrospective observational study based on the analysis of physical and electronic records of the evolution of acute or chronic renal insufficiency patients through active search in immunosuppressive dispensing tables. This study included records of 162 patients, and 118 of them had one or more possible immunosuppressive reactions. We observed that the most prevalent ADR in the study was “opportunistic infection” and the lowest prevalence “hypoalbuminemia.” For better result reliability, Naranjo’s algorithm was applied, where “infection” remained relevant in 26% of its cases classified by the algorithm as “probable.” Given the results, the importance of the clinical pharmacist in the optimization of the immunosuppressive pharmacotherapy 
used by the renal insufficient patients of the hospital in question is observed.

Author Biographies

Fernanda Toaldo, Pontifícia Universidade Católica do Paraná - PUCPR Rua Imac. Conceição, 1155 - Prado Velho, Curitiba - PR, 80215-901

Farmacêutica graduada pela PUCPR em 2018. Atualmente Residente no Hospital Pequeno Príncipe.

Flavia Lorenzen dos Santos, Pontifícia Universidade Católica do Paraná - PUCPR Rua Imac. Conceição, 1155 - Prado Velho, Curitiba - PR, 80215-901

Farmacêutica graduada pela PUCPR em 2018. Atualmente Analista Comercial e da Qualidade na Formathos Fornecedora de Material Hospitalar Ltda.

Fernanda Cristina Ostrovski Sales, Pontifícia Universidade Católica do Paraná - PUCPR Rua Imac. Conceição, 1155 - Prado Velho, Curitiba - PR, 80215-901

Farmacêutica graduada pela UFPR em 2001. Especialista em Ciências Farmacêuticas com Ênfase em Atenção Farmacêutica pela UFPR em 2007. Mestre em Tecnologia em Saúde pela PUCPR em 2014, atualmente Doutoranda pro Programa de Pós Graduação em Odontologia da PUCPR com Ênfase em Saúde Coletiva e docente nos cursos de Farmácia, Medicina e Odontologia da PUCPR.

Jaqueline de Jesus Aschenbrenner, Pontifícia Universidade Católica do Paraná - PUCPR Rua Imac. Conceição, 1155 - Prado Velho, Curitiba - PR, 80215-901

Farmacêutica graduada em 2012 pela Faculdade Pequeno Príncipe. Especialista em Farmácia Clínica pela Faculdade Pequeno Príncipe em 2015. Atualmente como Farmacêutica Clínica e Hospitalar no Hospital Universitário Cajuru desde 2013.

Downloads

Published

2020-12-08

How to Cite

Toaldo, F., dos Santos, F. L., Sales, F. C. O., & Aschenbrenner, J. de J. (2020). SAFETY ANALYSIS OF THE IMMUNOSUPPRESSANTS USE IN RENAL FAILURE PATIENTS. Infarma - Pharmaceutical Sciences, 32(4), 374–382. https://doi.org/10.14450/2318-9312.v32.e4.a2020.pp374-382

Issue

Vol. 32 No. 4 (2020)

Section

Original article

License

Authors who publish in this journal agree to the following terms:

 

  1. Authors retain the copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Licença Creative Commons Attribution which allows the sharing of work with acknowledgment of authorship and initial publication in this journal.
  2. Authors are authorized to take additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (e.g. publish in institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal.
  3. Authors are allowed and encouraged to publish and distribute their work online (e.g. in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes as well as increase the impact and Citation of published work (See O Efeito do Acesso Livre ).